Revlon brand manager
This article was originally published in The Rose Sheet
Executive Summary
Former Clairol International President Debra Leipman-Yale brings 24 years of beauty experience to Revlon brand VP and global general manager post, company says. Exec, who will be tasked with turning around Revlon cosmetics' declining market share, reports to newly appointed President and CEO Jack Stahl effective April 15. Appointment follows departure of Revlon Brand Equity Group Exec VP and General Manager Cheryl Vitali on the heels of CEO Jeffrey Nugent's exit in February (1"The Rose Sheet" Feb. 5, 2002, p. 6). Leipman-Yale, who joined Clairol in 1983 as associate brand manager, has served as director of haircolor marketing, VP of international marketing and category development and senior VP and general manager for Clairol Professional. She started her career in beauty in field sales at Revlon in 1978 and later became brand manager for Almay...
You may also be interested in...
Revlon promotions
Debra Leipman-Yale tapped as exec VP and chief marketing officer, a new position in which she will manage the entire Revlon, Inc. portfolio, company announces May 22. Exec will continue to report to CEO Jack Stahl. Leipman-Yale joined Revlon a year ago as exec VP and global general manager for the Revlon brand (1"The Rose Sheet" April 15, 2002, In Brief). Company also announces appointment of Rochelle Udell to exec VP and chief creative officer from her current role as exec VP, creative development and design. Senior VP of Human Resources Herbert Vallier has been promoted exec VP-human resources. Appointments are effective immediately...
Revlon Brand Management Responsibilities To Be Assigned By New CEO Stahl
One of the first tasks facing Revlon's newly-appointed President and CEO Jack Stahl will be delegating management duties for the company's key Revlon brand following the resignation of Revlon Brand Equity Group Exec VP and General Manger Cheryl Vitali
Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use
The CEO and CSO of radiopharmaceutical company Ratio Therapeutics, which now has Bristol Myers Squibb as an investor, talk about Ratio’s R&D platforms, use of AI, an independent FAP-targeted asset and trends in radiopharma research such as combining other modalities like ADCs, in this podcast interview with Scrip